Global

  1. Global—English
  2. 中国—简体中文

Newsroom

Strive to Deliver Breakthroughs

HOME / Newsroom / Press Release
Press Release
  1. June 15, 2026

    Epic Victory! Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

    The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's ...

    View more
  2. June 12, 2026

    Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — June 11, 2026   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical...

    View more
  3. June 11, 2026

    Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — June 10, 2026   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical...

    View more
  4. June 10, 2026

    Harbour BioMed Announces NMPA Acceptance of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — June 10, 2026                &...

    View more
  5. June 09, 2026

    First Patients Dosed in Phase 2 SIRIUS COPD Study of HBM9378/WIN378, a Fully Human Ultra Long-Acting Anti-TSLP Antibody

    COPD study initiation expands HBM9378/WIN378 (also known as SKB378) development into a second major respiratory disease HBM9378/WIN378 is currently being ...

    View more
  6. May 18, 2026

    Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — May 18, 2026   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical ...

    View more
  7. May 08, 2026

    Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid Tumors

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — May 8, 2026   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical c...

    View more
  8. May 08, 2026

    Harbour BioMed Invests in Windward Bio’s $165M Financing to Advance Pipeline of Long-Acting Immunology Therapies

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — May 7, 2026   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceuti...

    View more
  9. April 16, 2026

    Harbour BioMed Appoints Dr. Adam Zong as President

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — April 16, 2026   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutica...

    View more
  10. March 30, 2026

    Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — March 30, 2026   Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a...

    View more

Follow
Harbour BioMed
on WeChat

Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号 沪ICP备19015946号-1

FAMILY SITE

中文
ENG